Genetic variant of IL28B rs12979860, as predictive marker of interferon-based therapy in Pakistani population

APMIS

Volumn 123, Issue 4, 2015, Pages 342-349

  Imran, Muhammad ^a   Manzoor, Sobia ^a   Azam, Sikandar ^a   Resham, Saleha ^a  

^a NATIONAL UNIVERSITY OF SCIENCES AND TECHNOLOGY   (Pakistan)

Author keywords

Genotypes; Hepatitis; Interferon therapy; Polymorphism; Responders

Indexed keywords

INTERFERON; INTERLEUKIN 28B; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; GENETIC MARKER; IL28B PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN;

ADULT; ALLELE; ANTIVIRAL THERAPY; ARTICLE; CHRONIC HEPATITIS; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE ASSOCIATION; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; MAJOR CLINICAL STUDY; MALE; PAKISTANI; POPULATION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS TITRATION; DRUG COMBINATION; GENETIC MARKER; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PAKISTAN; POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

ADULT; ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GENETIC MARKERS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; PAKISTAN; POLYETHYLENE GLYCOLS; POLYMERASE CHAIN REACTION; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; POLYMORPHISM, SINGLE NUCLEOTIDE; RECOMBINANT PROTEINS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84925326737     PISSN: 09034641     EISSN: 16000463     Source Type: Journal    
DOI: 10.1111/apm.12365     Document Type: Article

References (47)

1. Alter HJ, Purcell RH, Shih JW, Melpolder JC, Houghton M, Choo Q-L, et al. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med 1989;321:1494-500.
2. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005;5:558-67.
3. Younossi Z, Kallman J, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology 2007;45:806-16.
4. Kieffer TL, Sarrazin C, Miller JS, Welker MW, Forestier N, Reesink HW, et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007;46:631-9.
5. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-82.
6. Hadziyannis S, Sette H Jr, Morgan T, Balan V, Diago M, Marcellin P, et al. PEGASYS International Study Group: Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346-55.
7. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol 2006;44:97-103.
8. Shiffman ML. Hepatitis C virus therapy in the direct acting antiviral era. Curr Opin Gastroenterol 2014;30:217-22.
9. Idrees M, Riazuddin S. Frequency distribution of hepatitis C virus genotypes in different geographical regions of Pakistan and their possible routes of transmission. BMC Infect Dis 2008;8:69.
10. Idrees M, Riazuddin S. A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients. BMC Gastroenterol 2009;9:5.
11. Cooper S, Erickson AL, Adams EJ, Kansopon J, Weiner AJ, Chien DY, et al. Analysis of a successful immune response against hepatitis C virus. Immunity 1999;10:439-49.
12. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005;5:215-29.
13. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, et al. The natural history of hepatitis C virus infection. J Am Med Assoc 2000;284:450-6.
14. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006;44:896-906.
15. Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, Paludan SR. Lambda interferon (IFN-λ), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006;80:4501-9.
16. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I, et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and λ interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004;34:796-805.
17. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'hUigin C, et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009;461:798-801.
18. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;461:399-401.
19. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy. Nat Genet 2009;41:1100-4.
20. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C. Nat Genet 2009;41:1105-9.
21. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T, et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 2010;138:1338-45.
22. Mangia A, Thompson AJ, Santoro R, Piazzolla V, Tillmann HL, Patel K, et al. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response. Gastroenterology 2010;139:821-7.
23. Adam R, McMaster P, O'Grady JG, Castaing D, Klempnauer JL, Jamieson N, et al. Evolution of liver transplantation in Europe: report of the European Liver Transplant Registry. Liver Transpl 2003;9:1231-43.
24. Watt K, Veldt B, Charlton M. A practical guide to the management of HCV infection following liver transplantation. Am J Transplant 2009;9:1707-13.
25. Ackefors M, Nyström J, Wernerson A, Gjertsen H, Sönnerborg A, Weiland O. Evolution of fibrosis during HCV recurrence after liver transplantation-influence of IL-28B SNP and response to peg-IFN and ribavirin treatment. J Viral Hepatitis 2013;20:770-8.
26. Hörnfeldt E, Gjertsen H, Weiland O. High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantation. Scand J Infect Dis 2008;40:259-65.
27. Angelico M, Petrolati A, Lionetti R, Lenci I, Burra P, Donato MF, et al. A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C. J Hepatol 2007;46:1009-17.
28. Zhang L, Lu Q, Yang Z, Wang X, Cai L, Liu X, et al. Association of rs12979860 and rs8099917 polymorphisms near IL28B with SVR in hepatic allograft recipients with HCV recurrence undergoing PEG-IFN/RBV therapy: a meta-analysis. Hum Immunol 2014;75:1268-75.
29. Rembeck K, Alsio A, Christensen PB, Farkkila M, Langeland N, Buhl MR, et al. Impact of IL28B-related single nucleotide polymorphisms on liver histopathology in chronic hepatitis C genotype 2 and 3. PLoS ONE 2012;7:13.
30. Rembeck K, Westin J, Lindh M, Hellstrand K, Norkrans G, Laging M. Association between interleukin-28B-related genetic variants and liver histopathology differs between hepatitis C virus genotypes. Hepatology 2012;56:394.
31. Imran M, Manzoor S, Khattak NM, Tariq M, Khalid M, Javed F, et al. Correlation of OAS1 Gene Polymorphism at Exon 7 Splice Accepter Site with Interferon-Based Therapy of HCV Infection in Pakistan. Viral Immunol 2014;27:105-11.
32. Imran M, Manzoor S, Parvaiz F. Predictive Potential of IL-18- 607 and Osteopontin- 442 Polymorphism in Interferon-Based Therapy of HCV Infection in the Pakistani Population. Viral Immunol 2014;27:404-11.
33. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009;49:1335-74.
34. McCaughan G, Omata M, Amarapurkar D, Bowden S, Chow W, Chutaputti A. Asian Pacific Association for the Study of the Liver (APASL) Hepatitis C Working Party. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007;22:615-33.
35. Ismail MH. Prediction of sustained virologic responses to combination therapy of pegylated interferon-α and ribavirin in patients with chronic hepatitis C infection. J Fam Commun Med 2013;20:35.
36. Imran M, Manzoor S, Ashraf J, Khalid M, Tariq M, Khaliq HM, et al. Role of viral and host factors in interferon based therapy of hepatitis C virus infection. Virol J 2013;10:299.
37. Aziz H, Athar MA, Murtaza S, Irfan J, Waheed Y, Bilal I, et al. Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population. Chin Med J 2011;124:1333-7.
38. Lindh M, Arnholm B, Eilard A, Färkkilä M, Hellstrand K, Lagging M, et al. Hepatitis C treatment response kinetics and impact of baseline predictors. J Viral Hepatitis 2011;18:400-7.
39. McHutchison JG. The role of genetic markers in hepatitis C virus therapy: a major step for individualized care. Liver International 2011;31:29-35.
40. Yan KK, Guirgis M, Dinh T, George J, Dev A, Lee A, et al. Treatment responses in Asians and Caucasians with chronic hepatitis C infection. World Journal of Gastroenterology: WJG 2008;14:3416.
41. Sivaprasad S, Rao PN, Gupta R, Ashwini K, Reddy DN. The distribution of genotype and allelic frequency of IL28B gene polymorphism in Andhra Pradesh, India. Journal of Clinical and Experimental Hepatology 2012;2:112-5.
42. Sharafi H, Pouryasin A, Alavian SM, Behnava B, Keshvari M, Mehrnoush L, et al. Development and validation of a simple, rapid and inexpensive PCR-RFLP method for genotyping of common IL28B polymorphisms: a useful pharmacogenetic tool for prediction of Hepatitis C treatment response. Hepat Monthly 2012;12:190-5.
43. Antaki N, Bibert S, Kebbewar K, Asaad F, Baroudi O, Alideeb S, et al. IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4. J Viral Hepatitis 2013;20:59-64.
44. Fischer J, Böhm S, Scholz M, Müller T, Witt H, George J, et al. Combined effects of different interleukin-28B gene variants on the outcome of dual combination therapy in chronic hepatitis C virus type 1 infection. Hepatology 2012;55:1700-10.
45. Jia Z, Ding Y, Tian S, Niu J, Jiang J. Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis. PLoS ONE 2012;7:e45698.
46. Moghaddam A, Melum E, Reinton N, Ring-Larsen H, Verbaan H, Bjøro K, et al. IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection. Hepatology 2011;53:746-54.
47. Sarrazin C, Susser S, Doehring A, Lange CM, Muller T, Schlecker C, et al. Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients. J Hepatol 2011;54:415-21.